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Abstract
Malignant gliomas are refractory to conventional thera-
pies, including surgery, radiotherapy and chemother-
apy. Thus, a variety of therapies such as the inhibition of
angiogenesis and signal transduction pathways have
been attempted. In the present study, we have evaluated
the combined effect of endostatin, an inhibitor of
angiogenesis, and a DNA enzyme targeting the protein
kinase CA (PKCA ) gene expression. Inhibition of PKCA
by a nuclease-resistant DNA enzyme eliminated PKCA
gene expression and induced apoptosis in most glioma
cells. To assess the efficacy of endostatin and the PKCA
DNA enzyme in vivo, rats bearing the intracranial tumor
BT4C were given a combined treatment of endostatin
and the PKCA enzyme. Survival was significantly en-
hanced by continuous delivery of endostatin (P<.0004)
and rats treated with a single injection of the active DNA
enzyme lived significantly longer than those treated with
the inactive form (P<.045). Interestingly, a single injec-
tion of the PKCA DNA enzyme in combination with con-
tinuous delivery of endostatin significantly improved
animal survival compared with PKCA (P<.0009) or en-
dostatin (P<.025) alone. Thus, the combined treatment
may represent an attractive therapeutic strategy against
malignant gliomas.
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Introduction
Resistance to chemotherapy and radiotherapy is a major
obstacle for the treatment of malignant gliomas that are
surgically incurable because of their diffusely infiltrative
nature. Glioblastoma multiforme is the most frequent and
most malignant glial neoplasm [1]. Thus, the search for
novel therapeutic approaches is clearly warranted.
Regulatory proteins involved in tumor cell proliferation and
angiogenesis are expected to be promising candidates for
gene therapy [2]. Some studies have shown that the
expression of Bcl -2–related proteins and the activation of
the mitogen activated protein kinase (MAPK) signaling
cascades are associated with malignant cell growth [2–6].
One of the protein kinases that was implicated in malignant
glioma cell proliferation is the protein kinase C (PKC) [7–9].
PKC exists as a family of at least 12 closely related
isoenzymes [10,11]. Because of the similarity in structure
characteristics among the different isoenzymes, it has been
difficult to develop isoenzyme-specific inhibitors and hence
to establish the physiological roles for each isoenzyme
member. One method to inhibit gene expression of related
isoenzymes is to use ribozymes or DNA enzymes [12].
Inhibition of gene function by this technology relies primarily
on Watson-Crick base pairing of nucleic acids. After binding,
catalytic nucleic acids are able to cleave their corresponding
target mRNAs [12–14]. In this respect, inhibition of protein
kinase Ca (PKCa ) gene expression by a nuclease-resistant
ribozyme or DNA enzymes blocked glioma cell proliferation
both in vitro and in vivo, leading to the conclusion that PKCa
is a key modulator of malignant glioma growth [9,12,15]. In
addition, some studies have supported the role of the PKCa
signaling pathway in the tumorigenicity and metastasis of
other malignancies such as breast and intestinal tumors
[7,16,17].
The formation of the vascular network is essential for
tumors to grow and metastasize [18]. Glioblastoma multi-
forme shows a high degree of proliferation of the microvascu-
lature, thus serving as suitable targets for anti–angiogenic
therapy [19,20]. To date, a number of inducers and inhibitors
of angiogenesis have been described [21–24]. Endostatin is
a 20-kDa cleavage product of the C-terminal domain of
collagen XVIII and was originally purified from a murine
hemangioendothelioma [24]. It has been shown to be a
potent anti–angiogenic factor in various neoplasias [25].
We have recently found that subcutaneous and intra-
cranial growth of gliosarcomas can be inhibited by endostatin
[26]. This inhibition was characterized by a reduction in both
tumor size, blood vessel volume and tumor blood flow as well
as increased apoptosis within the tumors. Notably, endostatin
was found to be more effective on subcutaneous tumor
growth compared with its intracranial counterpart. In this
respect, animal bearing intracranial tumors survived only
3 days longer than controls after daily administration of
endostatin [26].
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In addition to angiogenesis, several lines of evidence
indicate that autonomous growth of cancer cells is a
consequence of genetic alteration which affect signal trans-
duction pathways, in particular those which are implicated in
the control of cell proliferation [27]. We have previously
shown that the PKCa is important for glioma cell survival and
proliferation. Indeed, its targeting with nucleic acid enzymes
induced apoptosis and inhibited subcutaneous tumor growth
[9,12,15]. In the present paper, we explored the combined
effects of a PKCa DNA enzyme and endostatin on intra-
cranial tumor growth, both given locally.
Materials and Methods
Generation of Endostatin and the DNA Enzyme
Recombinant human endostatin expressed in the yeast
Picia pastoris [28] was used in this study. We used a DNA
enzyme (DRz4) targeting the translation start site AUG in
human PKCa mRNA that has been previously characterized
[12]. As control, a DNA enzyme with reversed antisense
arms (DRz4r) was used.
Cell Line
The BT4C tumor was derived from serial in vivo passages
of the BT4C tumor, originally induced from transformed fetal
rat brain cells after exposure to ethyl -nitrosourea [29]. The
BT4C cells were grown in RPMI medium with 10% heat-
inactivated newborn calf serum (FCS). The cell line was
tested negative for viral agents in a rat antibody production
test according to the Federation of Laboratory Animal
Association recommendations [30].
In Vitro Activity of the DNA Enzyme
BT4C cells were seeded in 96-well tissue culture plates at
a density of 103 cells per well in 100 l complete RPMI
medium. After incubation for at least 6 hours at 378C, cells
were transfected with the test molecules as described pre-
viously [9 ]. Briefly, the appropriate concentration of DNA
enzyme was mixed with 2 g cationic liposomes (DOTAP;
Boehringer Mannheim) and transfection buffer (25 mM
HEPES, pH 7.4), yielding a final volume of 10 l. The mixture
was vortexed and incubated at room temperature for at least
10 minutes before adding to cell cultures. After 40 hours
transfection time, viable cell number was assessed by the
MTT assay [12].
To analyze the kinetics of uptake of the DNA enzyme by
glioma cells, BT4C cells were seeded 10
4 cells per well in
100 l RPMI complete medium and then transfected with a
fluorescein- tagged DRz4 (200 nM) as described above. At
various time points, cells (within three wells ) were trypsi-
nated, washed and then analyzed by flow cytometry.
Western Blots
Protein extracts were prepared from control and test
molecule- treated cells. Briefly, cells were washed twice with
phosphate-buffered saline (PBS) and lysed at 48C with
lysing buffer (0.2% NP40 in PBS and protease inhibitors).
After 20 to 30 minutes of incubation, cell lysates were
centrifuged for 10 minutes at 15,000 rpm and supernatant
was collected. Protein concentrations were determined using
the protein assay Kit (Bio-Rad Laboratories, Hercules, CA).
Equivalent amounts of cytoplasmic proteins (15 g) were
analyzed by 10% SDS-PAGE and transferred to nitro-
cellulose membranes. The membranes were blocked with
5% BSA in immunoblotting buffer (10 mM Tris, 150 mMNaCl
and 0.1% Tween-20) overnight at 48C, and subsequently
incubated with rabbit IgG polyclonal anti -PKCa, anti–Bcl -xL
or b -actin antibodies. After washing, membranes were
incubated with horseradish peroxidase conjugated anti–
rabbit IgG antibody. The immunoreactive proteins were
visualized by an ECL detection Kit (Amersham).
Analysis of Apoptosis by the TUNEL-Method
A commercially available in situ cell death fluorescein
detection kit based on terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP-FITC nick end labeling (TUNEL)
was used (Boehringer, Ingelheim, Germany). In these
experiments, glioma cells were transfected for 48 hours
and then they were detached from the plates by gentle
scraping. The cells were thereafter collected by centrifuga-
tion, washed with PBS, fixed with 4% paraformaldehyde and
then permeabilized with 0.1% Triton X-100 in 0.1% sodium
citrate for 2 minutes at 48C. After washing with PBS, cells
were incubated with the TUNEL-reagents for 30 minutes,
washed with PBS and then analyzed by flow cytometry
(Becton Dickinson). TUNEL positive cells were gated, and
the results were analyzed by CELLQuest software.
Animals
Inbred BD-IX rats (Harlan Olac, Bicester, UK) of both
sexes weighing at least 250 g were caged in pairs or groups
of three animals in Macrolon III cages. The animal holding
rooms were maintained at constant temperature and hu-
midity on a 12-hour light and dark schedule at an air ex-
change rate of 18 changes/hour. Animal care and protocol
were in accordance with national legislation and institutional
guidelines. The animals were tested negative for parasitical,
bacterial and viral agents according to the FELASA recom-
mendations [30]. For the surgical procedures, the rats were
anaesthetized with a combination of fentanyl / fluanisone and
midazolam, and buphrenorphin was used as a postoperative
analgetic agent. The rats were euthanized with a lethal dose
of pentobarbitone i.p. (100 mg/kg). Treatment and control
groups consisted of seven animals each.
The Rat Gliosarcoma Model
To establish intracranial tumors, the anaesthetized rats
were fixed in a stereotactic frame (David Kopf Instruments,
Tujunga, CA), before the skin was incised and a 1.0-mm
burr hole was made to fit the coordinates (3.3 mm posterior
to and 2.5 mm to the right of the bregma, depth 2.8 mm). The
injection device consisted of a 30-G blunt needle connected
through a catheter (Small Parts, Miami Lakes, FL) to an
infusion pump (Harvard Apparatus, Holliston, MS). The
needle was fixed in the electrode holder of the stereotactic
frame, and then vertically introduced into the brain. A total of
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50,000 cells in 5 l of RPMI were injected into the brain
during a period of 1 minute. The needle was kept in place for
2 minutes and then slowly retracted. Closure was done with
bone wax and sutures.
Treatment Protocol
Human endostatin was administered using osmotic
mini pumps (Alzet, Mountain View, CA). The pumps was
positioned subcutaneous on the back of the animal,
connected to a brain infusion kit delivering a continuous
infusion of 5 l /hour (3 mg endostatin /24 hours) for up to
28 days at the same location where the tumor cells were
inoculated 3 days earlier. The DRz4 enzyme (100 g), or
its inactive form DRz4r (100 g) in 5 l saline, were
administered as a single intracranial injection on day 3,
using the stereotactic devise and injection apparatus at the
same coordinates as described above. The control animals
were treated with 0.9% NaCl during the same period.
Thereafter, the rats were examined regularly for local tumor
growth. The animals were euthanized with an overdose of
pentobarbitone when they showed a weight reduction of 10%
and/or clinical signs of raised intracranial pressure (reduced
activity, impaired locomotoric activity, and lethargy) and
were subsequently considered as death events in the
survival curves.
Statistical Analysis
Statistical analysis of the data was performed with the
Logrank test and significance was assumed for P<.05.
Results
Inhibition of Malignant Cell Growth by the DRz4 Enzyme
We have previously reported the development of a
nuclease- resistant PKCa DNA enzyme (DRz4) capable of
Figure 1. DRz4 uptake by glioma cells and its effect on viable cell number. (A ) DNA enzyme uptake by BT4C cells. Cells were transfected with a fluorescein - tagged
DRz4 (200 nM) using DOTAP (2 g ). Samples were taken at various time points and analyzed by flow cytometry. Values are means±SEM based on three
experiments. (B ) A fluorescent image of glioma cells transfected with a fluorescein - tagged DRz4 for 7 hours. Cells were transfected for 7 hours using the same
conditions as in A, and then analyzed by an epifluorescent microscope. (C ) BT4C glioma cells were transfected for 40 hours with the test molecules ( 200 nM) and
viable cell number was estimated with the MTT assay. The reduction of viable cell number was expressed as a percentage of that obtained in untreated cells.
DRz4=active DNA enzyme, DRz4r= inactive DNA enzyme. Values are means±SEM, n=4.
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inducing apoptosis in sensitive cells such as human
malignant gliomas [12]. To further investigate its potential
therapeutic use, in vitro and in vivo studies with rat malignant
gliomas were performed. We have assessed the uptake of
the DNA enzyme DRz4 into BT4C cells. In these experi-
ments, cells were transfected to a 50 - fluorescein–tagged
DRz4 enzyme and samples were taken at various time
points. To remove membrane-bound molecules, cells were
trypsinated, washed and then analyzed by flow cytometry.
Figure 1A shows that by 4 hours, almost all the cells had
taken up the DNA enzyme.
To establish whether the ribozyme crossed the cell
membrane and entered the cytoplasm and/or the nucleus
to inhibit PKCa gene expression, cells were analyzed by an
epifluorescent microscope. In these experiments, BT4C cells
were cultured on chamber slides and transfected with
fluorescein- tagged DNA enzyme. Upon examination, these
cells demonstrated almost 100% transfection efficiency
(Figure 1B ) as has been shown for human gliomas [12].
Notably, a high fraction of the DNA enzyme exhibited a
nuclear localization. Taken together, these results would
indicate that the experimental conditions in relation to
DOTAP (15 g/ml) and ribozyme concentration (100 to
200 nM) seems to be adequate for glioma cells.
To examine the effect of DRz4 on cell survival, BT4C
cells were transfected with the DRz4 enzyme or its inactive
form (DRz4r), and viable cell number was monitored by the
MTT assay (Figure 1C ). Notably, viable cell number was
reduced by 80% compared with that of DOTAP-treated
cells. In contrast, the inactive DNA enzyme (DRz4r) showed
only 15% inhibition, hence significantly lower than its ac-
tive form.
Effects of the DRz4 Enzyme on PKC Gene Expression
To evaluate whether the reduction in cell number after
DNA enzyme treatment was reflected at the protein level,
protein extracts from controls and DNA enzyme- treated cells
were subjected to Western blot analysis (Figure 2A ). In DNA
enzyme-treated cells, the protein level of PKCa was nearly
eliminated, whereas no significant effects were observed
with the inactive DNA enzyme. The observed inhibitory effect
was specific, because the protein level of a cross-reactive
protein, indicated by the open arrow, was not affected by the
DRz4 treatment (Figure 2B, lower panel ). Additionally, the
protein level of b -actin was not affected by the treatment
(data not shown). The secondary band seen in Western blot
is more likely to be a cross- reactive protein, because it
reacted with only one polyclonal antibody preparation. No
reactivity was seen with other antibodies specific for PKC-a
[9 ]. As we have reported previously, the inhibition of PKCa
gene expression by an RNA ribozyme or a DNA enzyme also
affected the Bcl -xL gene expression.
The downregulation of Bcl -xL may indicate that cells are
killed by apoptosis. Thus, we analyzed the extent of this
process in the presence and absence of the DNA enzyme
(Figure 2C ). In contrast to DOTAP-treated cells, where 15%
of the cells were apoptotic, 82% of the DNA enzyme-treated
cells were apoptotic. This result would confirm our previous
data that the overexpression of PKCa is required for glioma
cell survival and proliferation [12].
Therapeutic Effects of the Combined Treatment with the
DRz4 Enzyme and Endostatin on Intracranial Tumor Growth
To test the efficacy of the DRz4 molecules in vivo, rats
with intracerebrally implanted BT4C glioma cells were treated
with a single intracranial injection of the test molecules 3
days after cell inoculation. As shown in Figure 3A, there was
a significant difference in the survival times between animals
that had been treated with the active DRz4 enzyme
compared with those treated with the inactive enzyme
DRz4r. Rats treated with a continuous intracranial delivery
of endostatin lived significantly longer than untreated
controls (Figure 3B ).
To evaluate the effects of the combined treatment, rats
were given a single intracranial injection of the DRz4 enzyme
(100 g) on day 3 after inoculation in combination with
continuous intracranial delivery of endostatin (3 mg/kg per
24 hours). As illustrated in Figure 3B, rats treated with both
Figure 2. Effects of the DRz4 enzyme on gene expression and of apoptosis. After 40 hours transfection time, cytoplasmic protein extracts were prepared from
control (DOTAP) and DRz4 - and DRz4r - treated cells. Fifteen micrograms from each sample was analyzed byWestern blots using specific antibodies (A ). The final
concentrations of the DRz4 and DRz4r are indicated. A potential cross - reactive protein is indicated by the open arrow. A higher exposure of the data is shown in B.
(C ) Quantification of cellular DNA fragmentation by the TUNEL method. Controls and DRz4 - treated cells were analyzed by the TUNEL method as described in
Materials and Methods section. Of the DNA enzyme - treated cells, 82% were apoptotic. Cells were transfected for 48 hours.
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molecules lived longer (P<.025) (mean 29.1 days) than rats
treated with endostatin only (mean 26.0 days).
Discussion
The failure of malignant gliomas to respond to current
therapy prompted us to test the efficacy of a combined
targeting of the PKCa gene expression and tumor angio-
genesis. The designed DRz4 enzyme inhibited PKCa gene
expression and reduced viable cell number. Animals treated
with a single injection of the DRz4 survived longer than those
treated with the inactive DNA enzyme. The combination of
both endostatin and DRz4 improved animal survival com-
pared with single treatments.
Most brain tumors are characterized by a high recurrence
rate, in particular malignant gliomas that remain resistant to
all current treatment strategies [31]. Suppression of pro-
grammed cell death was found to be one of the main
mechanisms responsible for drug resistance [32]. In this
regard, glioma cells overexpressed the anti–apoptotic
protein Bcl -xL [9 ]. Thus, understanding the mechanisms
underlying the overexpression of the Bcl -xL protein in glioma
cells is important for the design of apoptotic agents. We have
previously found that the expression and/or activity of Bcl -xL
is under the control of the PKCa -signaling pathway in
malignant gliomas [9]. As shown in this study, specific
inhibition of PKCa by the DRz4 enzyme also inhibited Bcl -xL
gene expression. Interestingly, both the PKCa and Bcl -xL
were found to be localized in the mitochondrial membrane,
thus suggesting a direct interaction between these proteins
[12]. Similarly, PKCa was found to interact with the anti–
apoptotic protein Bcl -2. In this respect, phosphorylation of
Bcl -2 at Ser-70 by PKCa inhibited apoptosis induced by
chemotherapeutic drugs such as VP16 [32]. Thus, these
observations would define PKCa as a central regulator of
both cell proliferation and survival.
With the potential to induce apoptosis in sensitive cells,
the developed PKCa DNA enzyme should constitute an
important therapeutic tool [12]. Consistent with its anti–
proliferative effects on malignant gliomas growing in vitro, a
single injection of the DRz4 enzyme produced a significant
inhibitory effect on intracranial tumor growth in vivo. This
finding is in agreement with the idea that constitutive
activation of PKC, in particular the PKCa isoform, is required
for malignant tumor growth [9,12,33,34].
Endostatin was found to be a potent inhibitor of angio-
genesis [21,24]. In this respect, recombinant human endo-
statin was shown to induce regression and prevent growth of
subcutaneous experimental tumors when administered in
daily doses as high as 20 mg/kg [24]. Given the inhibitory
effects on tumor growth in nude mice [21] and glioma cells
growing subcutaneously in rats, it is possible that the in-
hibition of endothelial cell migration was inhibited [35]. In line
with this, we recently have shown that the angiogenic
process is indeed inhibited [36].
Although locally continuous administration with endostatin
has prolonged survival among rats with intracranial tumors
compared with daily subcutaneous injections, the observed
effect is still not quite impressive. Endostatin- treated rats
survived only 5 days longer than untreated controls. Various
mechanisms might account for the low effect of endostatin
on intracranial gliosarcoma growth. For example, other
angiogenic pathways, which are independent of endostatin,
may be involved. This points to the importance of targeting
additional pathways responsible for cell proliferation and
angiogenesis. Indeed, rats treated with both endostatin and
DRz4 enzyme survived 9 days longer than controls
(P<.025). In addition to being involved in glioma cell
proliferation, PKCa was found to regulate the expression of
bFGF [37], a potent angiogenic factor for gliomas. There-
fore, the mechanism of PKCa may also be angiogenic
inhibition, as well as the tumor effects previously demon-
strated. In contrast to gene and cell therapy approaches
[21,38], locally delivered drugs (e.g., recombinant proteins
and nucleic acid enzymes) are expected to be safer.
Injection of the ribozyme DOTAP/formulation into the brain
of control rats (without tumors) had no apparent cytotoxic
effects after 3 months observation period.
Taken together, the present data show that intracranial
inoculated glioma cells respond to a combined treatment with
locally applied DRz4 enzyme and endostatin. It will be of
interest to explore if this combined treatment may inhibit the
growth of other tumors.
Figure 3. Kaplan -Meier survival curves of rats with BT4C brain tumors. Rats
were inoculated with BT4C glioma cells. After 3 days, they were treated with
either a single injection of DRz4 or DRz4r enzyme (A ) ( n=7 ). The effects of a
continuous delivery of endostatin or a combination of the two treatment
modalities are shown in B (n=7 ).
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